ClinicalTrials.gg
CompletedNCT04543591Updated Nov 4, 2026Results posted

Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant

A Phase 3 interventional study of Ravulizumab and Placebo in Thrombotic Microangiopathy, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 66 sites in 17 countries. Open to participants aged 12 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment

Updated Nov 4, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
148
Allocation
Randomized
Ages
12 Years to 100 Years
Sex
All
01

Study summary

This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of ravulizumab in adult and adolescent participants with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). In Stage 1, an open-label, single-arm period, the dosing regimen will be confirmed. In Stage 2, participants will be randomized to receive either blinded ravulizumab plus best supportive care or matching placebo plus best supportive care. The treatment period is 26 weeks (open-label for Stage 1, and randomized, double-blind, and placebo-controlled for Stage 2) followed by a 26-week follow-up period.

02

Conditions studied

  • Thrombotic Microangiopathy

Keywords

  • Thrombotic Microangiopathy (TMA) Ultomiris
  • Ravulizumab
  • Hematopoietic Stem Cell Transplant (HSCT) Transplant-associated TMA
  • HSCT-TMA
03

In context

Thrombotic Microangiopathies

52 studies on the registry are indexed under Thrombotic Microangiopathies; 21 are open to participants now.

This study's enrollment of 148 is above the median of 40 across 24 interventional studies indexed under Thrombotic Microangiopathies.

Browse Thrombotic Microangiopathies studies →

Lead sponsor

Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.

Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.

First submitted before Alexion Pharmaceuticals, Inc. became part of AstraZeneca.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 12 years of age or older at time of consent/assent.
  2. Received within the past 12 months.
  3. Diagnosis of TMA that persists for at least 72 hours after initial management of any triggering agent/condition.
  4. A TMA diagnosis based on meeting the laboratory-based criteria during the Screening Period and/or ≤14 days prior to the Screening Period.
  5. Body weight ≥ 30 kilograms at Screening or ≤7 days prior to the start of the Screening Period (date of consent).
  6. Female participants of and male participants with female partners of childbearing potential must use highly effective .
  7. Participants must be vaccinated against meningococcal infections if clinically feasible. Participants who cannot receive meningococcal vaccine should receive antibiotic prophylaxis. Participants \<18 years of age must be re-vaccinated against Haemophilus influenzae type b (Hib) and Streptococcus pneumoniae if clinically feasible.
  8. Participants or their legally authorized representative must be capable of giving signed or assent.

Exclusion criteria

Exclusion Criteria:

  1. Thrombotic thrombocytopenic purpura (TTP) evidenced by ADAMTS13 deficiency
  2. Known Shiga toxin-related hemolytic uremic syndrome as demonstrated by positive test.
  3. Positive direct Coombs test indicative of a immune-mediated hemolysis not due to TMA.
  4. Clinical diagnosis of disseminated intravascular coagulation (DIC).
  5. Known bone marrow/graft failure for the current .
  6. Diagnosis of veno-occlusive disease which is unresolved at the time of Screening.
  7. (HIV) infection.
  8. Unresolved meningococcal disease.
  9. Presence of sepsis requiring vasopressor support.
  10. Pregnancy or breastfeeding.
  11. to murine proteins or to one of the of ravulizumab.
  12. Any ongoing or history of medical or psychological conditions unrelated to HSCT-TMA that could increase the risk to the participant or confound the outcome of the study.
  13. Respiratory failure requiring mechanical ventilation.
  14. Acute and/or chronic heart failure with an ≤ 40%.
  15. Previously or currently treated with a complement inhibitor.
  16. Participation in an interventional treatment study of any therapy for TMA.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
148 participants (actual)

Study arms

  • Experimental
    Ravulizumab

    In Stage 1, all participants will receive open-label ravulizumab plus Best Supportive Care (BSC). In Stage 2, participants will receive blinded ravulizumab plus Best Supportive Care (BSC).

    Biological: Ravulizumab · Other: Best supportive care

  • Placebo comparator
    Placebo

    In Stage 2, participants randomized to the placebo arm will receive matching placebo plus BSC.

    Other: Placebo · Other: Best supportive care

Interventions

  • BiologicalRavulizumab

    Weight-based doses of ravulizumab will be administered intravenously as loading dose regimen followed by maintenance dosing every 8 weeks.

    Also known as: Ultomiris, ALXN1210

  • OtherPlacebo

    Matching placebo

  • OtherBest supportive care

    Participants will receive medications, therapies, and interventions per standard hospital treatment protocols (unless specifically prohibited by the protocol).

06

What researchers measure

Primary outcomes

  1. Stage 2: Proportion of Participants With Event-free Survival During the 26-week Treatment Period

    Event-free survival was defined as the time from randomization until the first of the 2 following events: death (due to any cause) and clinical worsening up through Week 26. Clinical worsening was defined as meeting 2 or more of the following criteria: doubling of serum creatinine from baseline or new requirement of dialysis; increase in lactate dehydrogenase (LDH) \>25% compared to baseline; reduction in platelets of \>25% compared to baseline; reduction in hemoglobin \>10% compared to baseline; increased requirement for platelets or red blood cells at any time. The criteria for clinical worsening had to be confirmed by 2 independent samples collected at least 8 hours apart (ideally 24 hours apart).

    Time frame: Up to Week 26

Secondary outcomes

  1. Stage 2: Overall Survival

    The Kaplan-Meier method was used to measure overall survival estimate. For Day 100 and Week 26, overall survival was calculated from randomization to death (due to any cause), up to Day 100/Week 26. Participants who survived were censored at the earliest of an additional hematopoietic stem cell transplant (HSCT), Day 100/Week 26, or their last known date alive. For Week 52, overall survival was calculated from randomization to death (due to any cause), up to Week 52. Participants who survived were censored at the earlier of an additional HSCT, or their last known date alive up to Week 52.

    Time frame: Up to Day 100 (Treatment Period), Week 26 (Treatment Period), and Week 52 (Follow-up Period)

  2. Stage 2: Non-relapse Mortality

    Cumulative incidence for each group was estimated using a competing risks model. Non-relapse mortality was defined as a participant's death due to any cause during the study, with the exception of death due to underlying disease (malignant or non-malignant reason for HSCT) progression or relapse.

    Time frame: Baseline through Day 100 (Treatment Period), Week 26 (Treatment Period), and Week 52 (Follow-up Period)

  3. Stage 2: Mean Number of Thrombotic Microangiopathy (TMA) Response Criteria Met During the 26-week Treatment Period

    The TMA response parameters included: platelet response, normalization of LDH and absence of schistocytes, and renal response. A participant could have met 0, 1, 2, or 3 TMA response criteria during the 26-week Treatment Period. If the participants met more than 1 TMA response criterion, the number of responses overlapping for at least 24 hours was counted. Least squares mean determined from a general linear model adjusted by acute GVHD status and geographic region, assuming normal data distribution.

    Time frame: Baseline through Week 26

  4. Stage 2: Percentage of Participants With Hematologic Response During the 26-week Treatment Period

    Clinical laboratory assessments were performed according to the protocol and assessed against the following predetermined criteria for hematologic response: if baseline platelet count was ≤50000/cubic millimeter (mm\^3), then the absolute platelet count had to be \>50000/mm\^3 without platelet transfusion support during the prior 7 days; if the baseline platelet count had to be \>50000/mm\^3, then there must be a ≥50% increase in platelet count compared to baseline value without platelet transfusion support during the prior 7 days; normalization of LDH and absence of schistocytes (defined as ≤1% or a result of "none", per the International Council for Standardization in Hematology recommendations for schistocyte counting).

    Time frame: Baseline through Week 26

  5. Stage 2: Change From Baseline in the Estimated Glomerular Filtration Rate (eGFR) at Week 26 and Week 52

    The eGFR was calculated based on serum creatinine using the Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) formula. Serum creatinine was collected according to the protocol. Data reported as milliliters/minute/1.73 square meters (mL/min/1.73 m\^2).

    Time frame: Baseline, Week 26 (Treatment Period), Week 52 (Follow-up Period)

  6. Stage 2: Percentage of Participants With TMA Response During the 26-week Treatment Period

    The criteria for TMA response included a hematological response and a renal response. Hematological Response: if baseline platelet count was ≤50000/mm\^3, then the absolute platelet count had to be \>50000/mm\^3 without platelet transfusion support during the prior 7 days; if the baseline platelet count was \>50000/mm\^3, then there had to be a ≥50% increase in platelet count compared to baseline value without platelet transfusion support during the prior 7 days; normalization of LDH and absence of schistocytes. Renal response: at least 50% reduction of proteinuria from baseline. Participants must have met each of the response criteria, with each parameter meeting the requirements at 2 separate assessments obtained at least 24 hours apart, and any measurement in between. A participant could meet 0, 1, 2, or 3 TMA response criteria during the treatment period. If the participant met more than 1 TMA response criterion, the number of responses overlapping for at least 24 hours was counted.

    Time frame: Baseline through Week 26

  7. Stage 2: Cumulative Proportion of Participants Who Experienced a Complete TMA Response During the 26-week Treatment Period

    Cumulative proportion of participants who experienced a complete TMA response was estimated using a competing risks model based on the time (days) to complete TMA response. Time to complete TMA response was defined as the days from randomization to the first day during the 26-week Treatment Period on which a participant met all criteria for a complete TMA response. The date of complete TMA response was defined as the first date on which all individual response criteria were met simultaneously.

    Time frame: Baseline through Week 26

  8. Stage 2: Cumulative Proportion of Participants Experiencing Each Individual Component of TMA During the 26-week Treatment Period

    Cumulative proportion of participants experiencing individual TMA components included those for platelet count, LDH, and protein/creatinine ratio. For platelet count: if baseline platelet count was ≤50000/mm\^3, then the absolute platelet count had to be \>50000/mm\^3 without platelet transfusion support during the prior 7 days; if the baseline platelet count was \>50000/mm\^3, then there had to be a ≥50% increase in platelet count compared to baseline value without platelet transfusion support during the prior 7 days. For LDH: normalization of LDH and absence of schistocytes. For protein/creatinine ratio: at least 50% reduction of proteinuria from baseline.

    Time frame: Baseline through Week 26

  9. Stage 2: Cumulative Proportion of Participants Experiencing a Hematologic Response During the 26-week Treatment Period

    Clinical laboratory assessments were performed according to the protocol and assessed against the following predetermined criteria for hematologic response: if baseline platelet count was ≤50000/mm\^3, then the absolute platelet count had to be \>50000/mm\^3 without platelet transfusion support during the prior 7 days; if the baseline platelet count was \>50000/mm\^3, then there had to be a ≥50% increase in platelet count compared to baseline value without platelet transfusion support during the prior 7 days.

    Time frame: Baseline through Week 26

  10. Stage 2: Percentage of Participants With Hemoglobin Response During the 26-week Treatment Period

    Hemoglobin response was defined as the ability to maintain hemoglobin ≥10 grams/deciliter (g/dL) without any support. The criterion had to be met at 2 separate assessments obtained at least 24 hours apart, and any measurement in between, and without any support during the prior 7 days.

    Time frame: Baseline through Week 26

  11. Stage 2: Percentage of Participants With Platelet Response During the 26-week Treatment Period

    Platelet response was defined as: if baseline platelet count was ≤50000/mm\^3, then the absolute platelet count had to be \>50000/mm\^3 without platelet transfusion support during the prior 7 days; if the baseline platelet count was \>50000/mm\^3, then there had to be a ≥50% increase in platelet count compared to baseline value without platelet transfusion support during the prior 7 days. The criteria had to be met at 2 separate assessments obtained at least 24 hours apart, and any measurement in between.

    Time frame: Baseline through Week 26

  12. Stage 2: Percentage of Participants With Partial Response During the 26-week Treatment Period

    The criteria for TMA response included a hematological response and a renal response. Hematological response: if baseline platelet count was ≤50000/mm\^3, then the absolute platelet count had to be \>50000/mm\^3 without platelet transfusion support during the prior 7 days; if the baseline platelet count was \>50000/mm\^3, then there had to be a ≥50% increase in platelet count compared to baseline value without platelet transfusion support during the prior 7 days; normalization of LDH and absence of schistocytes. Renal response: at least 50% reduction of proteinuria from baseline. Partial response occurred when the participant met ≥1, but not all, criteria for TMA response.

    Time frame: Baseline through Week 26

  13. Stage 2: Percentage of Participants With Loss of TMA Response During the 26-week Treatment Period

    For participants that met the criteria for TMA response during the 26-week Treatment Period, loss of TMA response was defined as when the participant failed to meet the criteria for 1 or more components of TMA response at a subsequent visit during the 26-week Treatment Period. At least 1 parameter must have failed to meet the response criteria at 2 separate assessments obtained at least 24 hours apart, and any measurement in between.

    Time frame: Baseline through Week 26

  14. Stage 2: Duration of TMA Response

    This analysis includes data for each participant after achieving TMA response under the composite strategy through Weeks 26 and 52. The criteria for TMA response included a hematological response and a renal response. Time was calculated as the number of days from TMA response under the composite strategy to first loss of response or intercurrent event in the treatment period, or TMA relapse in the follow-up period. Participants must have met each of the response criteria, with each parameter meeting the requirements at 2 separate assessments obtained at least 24 hours apart, and any measurement in between. Participants with TMA response who did not experience these events were censored at their end of study date. The estimate is calculated based on the Kaplan-Meier method. Non-responders were counted as an event with a duration of zero day.

    Time frame: Baseline through Week 52

  15. Stage 2: Change From Baseline in Haptoglobin at Week 26 and Week 52

    Protocol-specified blood samples were taken for the analysis of haptoglobin in plasma at designated time points. Results are reported as grams/liter (g/L).

    Time frame: Baseline, Week 26 (Treatment Period), Week 52 (Follow-up Period)

  16. Stage 2: Change From Baseline in Platelets at Week 26 and Week 52

    Protocol-specified blood samples were taken for the analyses of platelets in plasma at designated time points.

    Time frame: Baseline, Week 26 (Treatment Period), Week 52 (Follow-up Period)

  17. Stage 2: Change From Baseline in LDH at Week 26 and Week 52

    Protocol-specified blood samples were taken for the analyses of LDH in plasma at designated time points. Results are reported as units/liter (U/L).

    Time frame: Baseline, Week 26 (Treatment Period), Week 52 (Follow-up Period)

  18. Stage 2: Change From Baseline in Hemoglobin at Week 26 and Week 52

    Protocol-specified blood samples were taken for the analyses of hemoglobin in plasma at designated time points.

    Time frame: Baseline, Week 26 (Treatment Period), Week 52 (Follow-up Period)

  19. Stage 2: Percentage of Participants With Modified TMA Response During the 26-week Treatment Period

    The modified criteria for TMA response included a hematological response and a renal response. Hematological Response: if baseline platelet count ≤50000/mm\^3, then the absolute platelet count had to be \>50000/mm\^3 without platelet transfusion support during the prior 7 days; if baseline platelet count \>50000/mm\^3, then there had to be a ≥50% increase in platelet count compared to baseline value without platelet transfusion support during the prior 7 days; at least 50% reduction of LDH from baseline and absence of schistocytes or normalization of LDH and absence of schistocytes. Renal response: at least 50% reduction of proteinuria from baseline. Participants must have met each response criterion, with each parameter meeting the requirement at 2 separate assessments obtained at least 24 hours apart, and any measurement in between.

    Time frame: Baseline through Week 26

  20. Stage 2: Change From Baseline in Number of Participants With TMA-associated Organ Dysfunction in the Renal System Through Week 26 and Week 52

    Renal dysfunction was defined as doubling of serum creatinine from baseline or requirement of dialysis. Requirements for dialysis included: at the baseline visit, if there was any dialysis within 5 days prior to the first dose of study treatment; at the post-baseline visit, if there was any dialysis within 5 days prior to the visit. Participants categorized as those experiencing no symptoms at baseline and those experiencing symptoms at baseline.

    Time frame: Baseline, Week 26 (Treatment Period), Week 52 (Follow-up Period)

  21. Stage 2: Change From Baseline in Number of Participants With TMA-associated Organ Dysfunction in the Cardiopulmonary System Through Week 26 and Week 52

    Cardiopulmonary dysfunction was defined as the presence of cardiopulmonary symptoms (excluding hypertension) or use of any mechanical ventilation. Cardiopulmonary symptoms included, but were not limited to, pleural effusion, pulmonary edema, pericardial effusion, and serositis. The presence of cardiopulmonary symptoms at baseline and post-baseline visits were assessed and recorded on the electronic case report form (eCRF). Use of any ventilatory or respiratory support, including mechanical ventilation, was reported on the participant's Nonpharmacologic Therapies and Procedures eCRF page. Participants categorized as those experiencing no symptoms at baseline and those experiencing symptoms at baseline.

    Time frame: Baseline, Week 26 (Treatment Period), Week 52 (Follow-up Period)

  22. Stage 2: Change From Baseline in Number of Participants With TMA-associated Organ Dysfunction in the Central Nervous System Through Week 26 and Week 52

    Central nervous system dysfunction was defined as confirmed posterior reversible encephalopathy syndrome, or any signs of headache, confusion, visual loss, or seizures at baseline and post-baseline visits, as recorded on the eCRF. Participants categorized as those experiencing no symptoms at baseline and those experiencing symptoms at baseline.

    Time frame: Baseline, Week 26 (Treatment Period), Week 52 (Follow-up Period)

  23. Stage 2: Change From Baseline in Number of Participants With TMA-associated Organ Dysfunction in the Gastrointestinal System Through Week 26 and Week 52

    Gastrointestinal dysfunction was defined as presence of signs and symptoms of gastrointestinal involvement at baseline and post-baseline visits, including diarrhea, vomiting, pain, and bleeding as recorded on the eCRF. Participants categorized as those experiencing no symptoms at baseline and those experiencing symptoms at baseline.

    Time frame: Baseline, Week 26 (Treatment Period), Week 52 (Follow-up Period)

  24. Stage 2: Percentage of Participants With TMA Relapse

    For participants that met the criteria for TMA response during the 26-week Treatment Period, TMA relapse was defined as evidence of worsening hematologic and renal dysfunction due to TMA during the post-treatment Follow-up Period and required treatment intervention, as determined by the investigator.

    Time frame: Baseline through Week 52

07

Results

Posted Nov 4, 2026

Participant flow

This study included 2 periods, each 26 weeks long: Treatment Period; Follow-up Period.

Treatment Period (26 Weeks)
Participant flow — Treatment Period (26 Weeks)
MilestoneRavulizumab: Stage 1Ravulizumab: Stage 2Placebo: Stage 2
Started206462
Received at least 1 dose of study drug206362
Full analysis set06462
Rescue ravulizumab: stage 20010
Completed63424
Not completed143038
Withdrew: Early discontinuation by participant001
Withdrew: Disease progression100
Withdrew: Lack of efficacy012
Withdrew: Withdrawal by subject025
Withdrew: Physician decision105
Withdrew: Death82723
Withdrew: Adverse event402
Follow-up Period (26 Weeks)
Participant flow — Follow-up Period (26 Weeks)
MilestoneRavulizumab: Stage 1Ravulizumab: Stage 2Placebo: Stage 2
Started63424
Completed42621
Not completed283
Withdrew: Other than specified001
Withdrew: Withdrawal by subject101
Withdrew: Physician decision010
Withdrew: Lost to follow-up010
Withdrew: Death161

Outcome measures

PrimaryStage 2: Proportion of Participants With Event-free Survival During the 26-week Treatment Period

Event-free survival was defined as the time from randomization until the first of the 2 following events: death (due to any cause) and clinical worsening up through Week 26. Clinical worsening was defined as meeting 2 or more of the following criteria: doubling of serum creatinine from baseline or new requirement of dialysis; increase in lactate dehydrogenase (LDH) \>25% compared to baseline; reduction in platelets of \>25% compared to baseline; reduction in hemoglobin \>10% compared to baseline; increased requirement for platelets or red blood cells at any time. The criteria for clinical worsening had to be confirmed by 2 independent samples collected at least 8 hours apart (ideally 24 hours apart).

Time frame:
Up to Week 26
Reported as:
Number · proportion of participants
Stage 2: Proportion of Participants With Event-free Survival During the 26-week Treatment Period
proportion of participantsRavulizumab: Stage 2Placebo: Stage 2
Stage 2: Proportion of Participants With Event-free Survival During the 26-week Treatment Period0.557 (0.427 to 0.669)0.475 (0.343 to 0.595)
Statistical analysis
  • Ravulizumab: Stage 2 vs Placebo: Stage 2 · Stratified Log-rank Test · p = 0.6386 (p-value based on stratified log-rank test comparing effect of treatment, with stratification by acute graft versus host disease (GVHD) status and geographic region.) · Hazard ratio (hr): 0.879 · 95% CI 0.526 to 1.467HR and confidence interval from a Cox proportional-hazards model with treatment, acute GVHD status, and geographic region.
SecondaryStage 2: Overall Survival

The Kaplan-Meier method was used to measure overall survival estimate. For Day 100 and Week 26, overall survival was calculated from randomization to death (due to any cause), up to Day 100/Week 26. Participants who survived were censored at the earliest of an additional hematopoietic stem cell transplant (HSCT), Day 100/Week 26, or their last known date alive. For Week 52, overall survival was calculated from randomization to death (due to any cause), up to Week 52. Participants who survived were censored at the earlier of an additional HSCT, or their last known date alive up to Week 52.

Time frame:
Up to Day 100 (Treatment Period), Week 26 (Treatment Period), and Week 52 (Follow-up Period)
Reported as:
Number · proportion of participants
Stage 2: Overall Survival
proportion of participantsRavulizumab: Stage 2Placebo: Stage 2
Day 1000.589 (0.458 to 0.698)0.632 (0.497 to 0.740)
Week 260.573 (0.442 to 0.684)0.490 (0.357 to 0.610)
Week 520.458 (0.332 to 0.576)0.453 (0.322 to 0.575)
SecondaryStage 2: Non-relapse Mortality

Cumulative incidence for each group was estimated using a competing risks model. Non-relapse mortality was defined as a participant's death due to any cause during the study, with the exception of death due to underlying disease (malignant or non-malignant reason for HSCT) progression or relapse.

Time frame:
Baseline through Day 100 (Treatment Period), Week 26 (Treatment Period), and Week 52 (Follow-up Period)
Reported as:
Number · proportion of participants
Stage 2: Non-relapse Mortality
proportion of participantsRavulizumab: Stage 2Placebo: Stage 2
Day 1000.395 (0.274 to 0.514)0.300 (0.189 to 0.419)
Week 260.411 (0.288 to 0.530)0.389 (0.264 to 0.512)
Week 520.509 (0.378 to 0.626)0.407 (0.280 to 0.531)
SecondaryStage 2: Mean Number of Thrombotic Microangiopathy (TMA) Response Criteria Met During the 26-week Treatment Period

The TMA response parameters included: platelet response, normalization of LDH and absence of schistocytes, and renal response. A participant could have met 0, 1, 2, or 3 TMA response criteria during the 26-week Treatment Period. If the participants met more than 1 TMA response criterion, the number of responses overlapping for at least 24 hours was counted. Least squares mean determined from a general linear model adjusted by acute GVHD status and geographic region, assuming normal data distribution.

Time frame:
Baseline through Week 26
Reported as:
Least squares mean · response criteria
Stage 2: Mean Number of Thrombotic Microangiopathy (TMA) Response Criteria Met During the 26-week Treatment Period
response criteriaRavulizumab: Stage 2Placebo: Stage 2
Stage 2: Mean Number of Thrombotic Microangiopathy (TMA) Response Criteria Met During the 26-week Treatment Period0.95 ± 0.1720.80 ± 0.172
SecondaryStage 2: Percentage of Participants With Hematologic Response During the 26-week Treatment Period

Clinical laboratory assessments were performed according to the protocol and assessed against the following predetermined criteria for hematologic response: if baseline platelet count was ≤50000/cubic millimeter (mm\^3), then the absolute platelet count had to be \>50000/mm\^3 without platelet transfusion support during the prior 7 days; if the baseline platelet count had to be \>50000/mm\^3, then there must be a ≥50% increase in platelet count compared to baseline value without platelet transfusion support during the prior 7 days; normalization of LDH and absence of schistocytes (defined as ≤1% or a result of "none", per the International Council for Standardization in Hematology recommendations for schistocyte counting).

Time frame:
Baseline through Week 26
Reported as:
Number · percentage of participants
Stage 2: Percentage of Participants With Hematologic Response During the 26-week Treatment Period
percentage of participantsRavulizumab: Stage 2Placebo: Stage 2
Stage 2: Percentage of Participants With Hematologic Response During the 26-week Treatment Period25.0 (15.0 to 37.4)17.7 (9.2 to 29.5)
SecondaryStage 2: Change From Baseline in the Estimated Glomerular Filtration Rate (eGFR) at Week 26 and Week 52

The eGFR was calculated based on serum creatinine using the Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) formula. Serum creatinine was collected according to the protocol. Data reported as milliliters/minute/1.73 square meters (mL/min/1.73 m\^2).

Time frame:
Baseline, Week 26 (Treatment Period), Week 52 (Follow-up Period)
Reported as:
Mean · mL/min/1.73 m^2
Stage 2: Change From Baseline in the Estimated Glomerular Filtration Rate (eGFR) at Week 26 and Week 52
mL/min/1.73 m^2Ravulizumab: Stage 2Placebo: Stage 2
Week 26-0.80 ± 27.920-2.95 ± 17.305
Week 52-2.60 ± 30.218-8.85 ± 16.898
SecondaryStage 2: Percentage of Participants With TMA Response During the 26-week Treatment Period

The criteria for TMA response included a hematological response and a renal response. Hematological Response: if baseline platelet count was ≤50000/mm\^3, then the absolute platelet count had to be \>50000/mm\^3 without platelet transfusion support during the prior 7 days; if the baseline platelet count was \>50000/mm\^3, then there had to be a ≥50% increase in platelet count compared to baseline value without platelet transfusion support during the prior 7 days; normalization of LDH and absence of schistocytes. Renal response: at least 50% reduction of proteinuria from baseline. Participants must have met each of the response criteria, with each parameter meeting the requirements at 2 separate assessments obtained at least 24 hours apart, and any measurement in between. A participant could meet 0, 1, 2, or 3 TMA response criteria during the treatment period. If the participant met more than 1 TMA response criterion, the number of responses overlapping for at least 24 hours was counted.

Time frame:
Baseline through Week 26
Reported as:
Number · percentage of participants
Stage 2: Percentage of Participants With TMA Response During the 26-week Treatment Period
percentage of participantsRavulizumab: Stage 2Placebo: Stage 2
Stage 2: Percentage of Participants With TMA Response During the 26-week Treatment Period18.8 (10.1 to 30.5)14.5 (6.9 to 25.8)
SecondaryStage 2: Cumulative Proportion of Participants Who Experienced a Complete TMA Response During the 26-week Treatment Period

Cumulative proportion of participants who experienced a complete TMA response was estimated using a competing risks model based on the time (days) to complete TMA response. Time to complete TMA response was defined as the days from randomization to the first day during the 26-week Treatment Period on which a participant met all criteria for a complete TMA response. The date of complete TMA response was defined as the first date on which all individual response criteria were met simultaneously.

Time frame:
Baseline through Week 26
Reported as:
Number · proportion of participants
Stage 2: Cumulative Proportion of Participants Who Experienced a Complete TMA Response During the 26-week Treatment Period
proportion of participantsRavulizumab: Stage 2Placebo: Stage 2
Stage 2: Cumulative Proportion of Participants Who Experienced a Complete TMA Response During the 26-week Treatment Period0.194 (0.105 to 0.301)0.151 (0.072 to 0.255)
SecondaryStage 2: Cumulative Proportion of Participants Experiencing Each Individual Component of TMA During the 26-week Treatment Period

Cumulative proportion of participants experiencing individual TMA components included those for platelet count, LDH, and protein/creatinine ratio. For platelet count: if baseline platelet count was ≤50000/mm\^3, then the absolute platelet count had to be \>50000/mm\^3 without platelet transfusion support during the prior 7 days; if the baseline platelet count was \>50000/mm\^3, then there had to be a ≥50% increase in platelet count compared to baseline value without platelet transfusion support during the prior 7 days. For LDH: normalization of LDH and absence of schistocytes. For protein/creatinine ratio: at least 50% reduction of proteinuria from baseline.

Time frame:
Baseline through Week 26
Reported as:
Number · proportion of participants
Stage 2: Cumulative Proportion of Participants Experiencing Each Individual Component of TMA During the 26-week Treatment Period
proportion of participantsRavulizumab: Stage 2Placebo: Stage 2
Platelet Count0.403 (0.278 to 0.525)0.274 (0.169 to 0.390)
LDH0.365 (0.247 to 0.484)0.290 (0.182 to 0.407)
Protein/Creatinine Ratio0.481 (0.351 to 0.600)0.419 (0.294 to 0.539)
SecondaryStage 2: Cumulative Proportion of Participants Experiencing a Hematologic Response During the 26-week Treatment Period

Clinical laboratory assessments were performed according to the protocol and assessed against the following predetermined criteria for hematologic response: if baseline platelet count was ≤50000/mm\^3, then the absolute platelet count had to be \>50000/mm\^3 without platelet transfusion support during the prior 7 days; if the baseline platelet count was \>50000/mm\^3, then there had to be a ≥50% increase in platelet count compared to baseline value without platelet transfusion support during the prior 7 days.

Time frame:
Baseline through Week 26
Reported as:
Number · proportion of participants
Stage 2: Cumulative Proportion of Participants Experiencing a Hematologic Response During the 26-week Treatment Period
proportion of participantsRavulizumab: Stage 2Placebo: Stage 2
Stage 2: Cumulative Proportion of Participants Experiencing a Hematologic Response During the 26-week Treatment Period0.257 (0.155 to 0.372)0.181 (0.095 to 0.289)
SecondaryStage 2: Percentage of Participants With Hemoglobin Response During the 26-week Treatment Period

Hemoglobin response was defined as the ability to maintain hemoglobin ≥10 grams/deciliter (g/dL) without any support. The criterion had to be met at 2 separate assessments obtained at least 24 hours apart, and any measurement in between, and without any support during the prior 7 days.

Time frame:
Baseline through Week 26
Reported as:
Number · percentage of participants
Stage 2: Percentage of Participants With Hemoglobin Response During the 26-week Treatment Period
percentage of participantsRavulizumab: Stage 2Placebo: Stage 2
Stage 2: Percentage of Participants With Hemoglobin Response During the 26-week Treatment Period26.6 (16.3 to 39.1)12.9 (5.7 to 23.9)
SecondaryStage 2: Percentage of Participants With Platelet Response During the 26-week Treatment Period

Platelet response was defined as: if baseline platelet count was ≤50000/mm\^3, then the absolute platelet count had to be \>50000/mm\^3 without platelet transfusion support during the prior 7 days; if the baseline platelet count was \>50000/mm\^3, then there had to be a ≥50% increase in platelet count compared to baseline value without platelet transfusion support during the prior 7 days. The criteria had to be met at 2 separate assessments obtained at least 24 hours apart, and any measurement in between.

Time frame:
Baseline through Week 26
Reported as:
Number · percentage of participants
Stage 2: Percentage of Participants With Platelet Response During the 26-week Treatment Period
percentage of participantsRavulizumab: Stage 2Placebo: Stage 2
Stage 2: Percentage of Participants With Platelet Response During the 26-week Treatment Period39.1 (27.1 to 52.1)27.4 (16.9 to 40.2)
SecondaryStage 2: Percentage of Participants With Partial Response During the 26-week Treatment Period

The criteria for TMA response included a hematological response and a renal response. Hematological response: if baseline platelet count was ≤50000/mm\^3, then the absolute platelet count had to be \>50000/mm\^3 without platelet transfusion support during the prior 7 days; if the baseline platelet count was \>50000/mm\^3, then there had to be a ≥50% increase in platelet count compared to baseline value without platelet transfusion support during the prior 7 days; normalization of LDH and absence of schistocytes. Renal response: at least 50% reduction of proteinuria from baseline. Partial response occurred when the participant met ≥1, but not all, criteria for TMA response.

Time frame:
Baseline through Week 26
Reported as:
Number · percentage of participants
Stage 2: Percentage of Participants With Partial Response During the 26-week Treatment Period
percentage of participantsRavulizumab: Stage 2Placebo: Stage 2
Stage 2: Percentage of Participants With Partial Response During the 26-week Treatment Period37.5 (25.7 to 50.5)40.3 (28.1 to 53.6)
SecondaryStage 2: Percentage of Participants With Loss of TMA Response During the 26-week Treatment Period

For participants that met the criteria for TMA response during the 26-week Treatment Period, loss of TMA response was defined as when the participant failed to meet the criteria for 1 or more components of TMA response at a subsequent visit during the 26-week Treatment Period. At least 1 parameter must have failed to meet the response criteria at 2 separate assessments obtained at least 24 hours apart, and any measurement in between.

Time frame:
Baseline through Week 26
Reported as:
Number · percentage of participants
Stage 2: Percentage of Participants With Loss of TMA Response During the 26-week Treatment Period
percentage of participantsRavulizumab: Stage 2Placebo: Stage 2
Stage 2: Percentage of Participants With Loss of TMA Response During the 26-week Treatment Period50.0 (21.1 to 78.9)33.3 (7.5 to 70.1)
SecondaryStage 2: Duration of TMA Response

This analysis includes data for each participant after achieving TMA response under the composite strategy through Weeks 26 and 52. The criteria for TMA response included a hematological response and a renal response. Time was calculated as the number of days from TMA response under the composite strategy to first loss of response or intercurrent event in the treatment period, or TMA relapse in the follow-up period. Participants must have met each of the response criteria, with each parameter meeting the requirements at 2 separate assessments obtained at least 24 hours apart, and any measurement in between. Participants with TMA response who did not experience these events were censored at their end of study date. The estimate is calculated based on the Kaplan-Meier method. Non-responders were counted as an event with a duration of zero day.

Time frame:
Baseline through Week 52
Reported as:
Median · days
Stage 2: Duration of TMA Response
daysRavulizumab: Stage 2Placebo: Stage 2
Stage 2: Duration of TMA Response166.0 (29.0 to NA)NA (38.0 to NA)
SecondaryStage 2: Change From Baseline in Haptoglobin at Week 26 and Week 52

Protocol-specified blood samples were taken for the analysis of haptoglobin in plasma at designated time points. Results are reported as grams/liter (g/L).

Time frame:
Baseline, Week 26 (Treatment Period), Week 52 (Follow-up Period)
Reported as:
Mean · g/L
Stage 2: Change From Baseline in Haptoglobin at Week 26 and Week 52
g/LRavulizumab: Stage 2Placebo: Stage 2
Week 261.111 ± 1.50201.162 ± 0.8224
Week 521.172 ± 1.04820.929 ± 0.5912
SecondaryStage 2: Change From Baseline in Platelets at Week 26 and Week 52

Protocol-specified blood samples were taken for the analyses of platelets in plasma at designated time points.

Time frame:
Baseline, Week 26 (Treatment Period), Week 52 (Follow-up Period)
Reported as:
Mean · platelets/mm^3
Stage 2: Change From Baseline in Platelets at Week 26 and Week 52
platelets/mm^3Ravulizumab: Stage 2Placebo: Stage 2
Week 26104777.8 ± 85403.2786333.3 ± 95082.01
Week 52153375.0 ± 91605.87130444.4 ± 113473.62
SecondaryStage 2: Change From Baseline in LDH at Week 26 and Week 52

Protocol-specified blood samples were taken for the analyses of LDH in plasma at designated time points. Results are reported as units/liter (U/L).

Time frame:
Baseline, Week 26 (Treatment Period), Week 52 (Follow-up Period)
Reported as:
Mean · U/L
Stage 2: Change From Baseline in LDH at Week 26 and Week 52
U/LRavulizumab: Stage 2Placebo: Stage 2
Week 26-339.4 ± 315.34-334.7 ± 288.12
Week 52-428.8 ± 337.68-338.6 ± 249.07
SecondaryStage 2: Change From Baseline in Hemoglobin at Week 26 and Week 52

Protocol-specified blood samples were taken for the analyses of hemoglobin in plasma at designated time points.

Time frame:
Baseline, Week 26 (Treatment Period), Week 52 (Follow-up Period)
Reported as:
Mean · g/dL
Stage 2: Change From Baseline in Hemoglobin at Week 26 and Week 52
g/dLRavulizumab: Stage 2Placebo: Stage 2
Week 262.292 ± 2.06071.689 ± 2.6146
Week 522.921 ± 2.34782.711 ± 2.8022
SecondaryStage 2: Percentage of Participants With Modified TMA Response During the 26-week Treatment Period

The modified criteria for TMA response included a hematological response and a renal response. Hematological Response: if baseline platelet count ≤50000/mm\^3, then the absolute platelet count had to be \>50000/mm\^3 without platelet transfusion support during the prior 7 days; if baseline platelet count \>50000/mm\^3, then there had to be a ≥50% increase in platelet count compared to baseline value without platelet transfusion support during the prior 7 days; at least 50% reduction of LDH from baseline and absence of schistocytes or normalization of LDH and absence of schistocytes. Renal response: at least 50% reduction of proteinuria from baseline. Participants must have met each response criterion, with each parameter meeting the requirement at 2 separate assessments obtained at least 24 hours apart, and any measurement in between.

Time frame:
Baseline through Week 26
Reported as:
Number · percentage of participants
Stage 2: Percentage of Participants With Modified TMA Response During the 26-week Treatment Period
percentage of participantsRavulizumab: Stage 2Placebo: Stage 2
Stage 2: Percentage of Participants With Modified TMA Response During the 26-week Treatment Period21.9 (12.5 to 34.0)16.1 (8.0 to 27.7)
SecondaryStage 2: Change From Baseline in Number of Participants With TMA-associated Organ Dysfunction in the Renal System Through Week 26 and Week 52

Renal dysfunction was defined as doubling of serum creatinine from baseline or requirement of dialysis. Requirements for dialysis included: at the baseline visit, if there was any dialysis within 5 days prior to the first dose of study treatment; at the post-baseline visit, if there was any dialysis within 5 days prior to the visit. Participants categorized as those experiencing no symptoms at baseline and those experiencing symptoms at baseline.

Time frame:
Baseline, Week 26 (Treatment Period), Week 52 (Follow-up Period)
Reported as:
Number · participants
Stage 2: Change From Baseline in Number of Participants With TMA-associated Organ Dysfunction in the Renal System Through Week 26 and Week 52
participantsRavulizumab: Stage 2Placebo: Stage 2
Week 26: Participants experiencing no symptoms at baseline1814
Week 26: Participants experiencing symptoms at baseline00
Week 52: Participants experiencing no symptoms at baseline2114
Week 52: Participants experiencing symptoms at baseline00
SecondaryStage 2: Change From Baseline in Number of Participants With TMA-associated Organ Dysfunction in the Cardiopulmonary System Through Week 26 and Week 52

Cardiopulmonary dysfunction was defined as the presence of cardiopulmonary symptoms (excluding hypertension) or use of any mechanical ventilation. Cardiopulmonary symptoms included, but were not limited to, pleural effusion, pulmonary edema, pericardial effusion, and serositis. The presence of cardiopulmonary symptoms at baseline and post-baseline visits were assessed and recorded on the electronic case report form (eCRF). Use of any ventilatory or respiratory support, including mechanical ventilation, was reported on the participant's Nonpharmacologic Therapies and Procedures eCRF page. Participants categorized as those experiencing no symptoms at baseline and those experiencing symptoms at baseline.

Time frame:
Baseline, Week 26 (Treatment Period), Week 52 (Follow-up Period)
Reported as:
Number · participants
Stage 2: Change From Baseline in Number of Participants With TMA-associated Organ Dysfunction in the Cardiopulmonary System Through Week 26 and Week 52
participantsRavulizumab: Stage 2Placebo: Stage 2
Week 26: Participants experiencing no symptoms at baseline106
Week 26: Participants experiencing symptoms at baseline0-4
Week 52: Participants experiencing no symptoms at baseline106
Week 52: Participants experiencing symptoms at baseline0-3
SecondaryStage 2: Change From Baseline in Number of Participants With TMA-associated Organ Dysfunction in the Central Nervous System Through Week 26 and Week 52

Central nervous system dysfunction was defined as confirmed posterior reversible encephalopathy syndrome, or any signs of headache, confusion, visual loss, or seizures at baseline and post-baseline visits, as recorded on the eCRF. Participants categorized as those experiencing no symptoms at baseline and those experiencing symptoms at baseline.

Time frame:
Baseline, Week 26 (Treatment Period), Week 52 (Follow-up Period)
Reported as:
Number · participants
Stage 2: Change From Baseline in Number of Participants With TMA-associated Organ Dysfunction in the Central Nervous System Through Week 26 and Week 52
participantsRavulizumab: Stage 2Placebo: Stage 2
Week 26: Participants experiencing no symptoms at baseline711
Week 26: Participants experiencing symptoms at baseline-2-3
Week 52: Participants experiencing no symptoms at baseline811
Week 52: Participants experiencing symptoms at baseline-2-3
SecondaryStage 2: Change From Baseline in Number of Participants With TMA-associated Organ Dysfunction in the Gastrointestinal System Through Week 26 and Week 52

Gastrointestinal dysfunction was defined as presence of signs and symptoms of gastrointestinal involvement at baseline and post-baseline visits, including diarrhea, vomiting, pain, and bleeding as recorded on the eCRF. Participants categorized as those experiencing no symptoms at baseline and those experiencing symptoms at baseline.

Time frame:
Baseline, Week 26 (Treatment Period), Week 52 (Follow-up Period)
Reported as:
Number · participants
Stage 2: Change From Baseline in Number of Participants With TMA-associated Organ Dysfunction in the Gastrointestinal System Through Week 26 and Week 52
participantsRavulizumab: Stage 2Placebo: Stage 2
Week 26: Participants experiencing no symptoms at baseline2012
Week 26: Participants experiencing symptoms at baseline-2-2
Week 52: Participants experiencing no symptoms at baseline2012
Week 52: Participants experiencing symptoms at baseline-2-2
SecondaryStage 2: Percentage of Participants With TMA Relapse

For participants that met the criteria for TMA response during the 26-week Treatment Period, TMA relapse was defined as evidence of worsening hematologic and renal dysfunction due to TMA during the post-treatment Follow-up Period and required treatment intervention, as determined by the investigator.

Time frame:
Baseline through Week 52
Reported as:
Number · percentage of participants
Stage 2: Percentage of Participants With TMA Relapse
percentage of participantsRavulizumab: Stage 2Placebo: Stage 2
Stage 2: Percentage of Participants With TMA Relapse28.6 (3.7 to 71.0)0.0 (0 to 41.0)

Adverse events

Collected over Day 1 through Week 52. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ravulizumab: Stage 1 - Treatment Period11/20 (55%)16/20 (80%)17/20 (85%)
Ravulizumab: Stage 2 - Treatment Period27/63 (42.9%)52/63 (82.5%)59/63 (93.7%)
Placebo: Stage 2 - Treatment Period31/62 (50%)44/62 (71%)54/62 (87.1%)
Rescue Ravulizumab: Stage 2 - Treatment Period7/10 (70%)10/10 (100%)9/10 (90%)
Ravulizumab: Stage 1 - Follow-up Period1/6 (16.7%)3/6 (50%)4/6 (66.7%)
Ravulizumab: Stage 2 - Follow-up Period7/34 (20.6%)11/34 (32.4%)19/34 (55.9%)
Placebo: Stage 2 - Follow-up Period1/21 (4.8%)7/21 (33.3%)10/21 (47.6%)
Rescue Ravulizumab: Stage 2 - Follow-up Period0/3 (0%)2/3 (66.7%)2/3 (66.7%)
Most frequent serious events
Showing 10 of 189
Most frequent serious events
EventRavulizumab: Stage 1 - Treatment PeriodRavulizumab: Stage 2 - Treatment PeriodPlacebo: Stage 2 - Treatment PeriodRescue Ravulizumab: Stage 2 - Treatment PeriodRavulizumab: Stage 1 - Follow-up PeriodRavulizumab: Stage 2 - Follow-up PeriodPlacebo: Stage 2 - Follow-up PeriodRescue Ravulizumab: Stage 2 - Follow-up Period
Respiratory tract infectionInfections and infestations0/201/631/620/100/60/340/211/3
Facial paralysisNervous system disorders0/200/630/620/100/60/340/211/3
Respiratory failureRespiratory, thoracic and mediastinal disorders0/202/631/622/100/60/340/210/3
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/202/630/620/101/60/340/210/3
HypoxiaRespiratory, thoracic and mediastinal disorders0/202/630/620/101/60/340/210/3
Bacterial infectionInfections and infestations0/200/630/620/101/60/340/210/3
MyelopathyNervous system disorders0/200/630/620/101/60/340/210/3
PneumoniaInfections and infestations3/201/636/621/100/61/340/210/3
Septic shockInfections and infestations0/208/633/621/100/60/340/210/3
Thrombotic microangiopathyBlood and lymphatic system disorders2/203/633/621/100/60/340/210/3
Most frequent other events
Showing 10 of 116
Most frequent other events
EventRavulizumab: Stage 1 - Treatment PeriodRavulizumab: Stage 2 - Treatment PeriodPlacebo: Stage 2 - Treatment PeriodRescue Ravulizumab: Stage 2 - Treatment PeriodRavulizumab: Stage 1 - Follow-up PeriodRavulizumab: Stage 2 - Follow-up PeriodPlacebo: Stage 2 - Follow-up PeriodRescue Ravulizumab: Stage 2 - Follow-up Period
COVID-19Infections and infestations0/203/636/620/103/60/340/210/3
Chronic graft versus host disease in skinImmune system disorders1/203/631/620/100/60/340/211/3
Chronic graft versus host disease oralImmune system disorders0/200/631/620/100/61/340/211/3
Chronic graft versus host disease in eyeImmune system disorders0/200/630/620/100/60/341/211/3
Blood creatinine increasedInvestigations1/202/635/620/100/60/340/211/3
HypokalaemiaMetabolism and nutrition disorders3/2011/6316/622/100/62/342/211/3
Pulmonary oedemaRespiratory, thoracic and mediastinal disorders0/201/634/620/100/60/340/211/3
PyrexiaGeneral disorders and administration site conditions3/2019/6312/620/100/62/343/210/3
Oedema peripheralGeneral disorders and administration site conditions6/205/638/621/100/62/340/210/3
Cytomegalovirus infection reactivationInfections and infestations4/2014/638/621/100/61/341/210/3

Baseline characteristics

All Enrolled Participants: all participants who signed the informed consent and were randomized in Stage 2 or were enrolled in Stage 1.

Age, Customized
Age, Customized(participants)Ravulizumab: Stage 1Ravulizumab: Stage 2Placebo: Stage 2Total
12 to <18 years1023
18 to <45 years2192041
45 to <65 years14312570
≥65 years3141532
Sex: Female, Male
Sex: Female, Male(Participants)Ravulizumab: Stage 1Ravulizumab: Stage 2Placebo: Stage 2Total
Female12363886
Male8282460
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Ravulizumab: Stage 1Ravulizumab: Stage 2Placebo: Stage 2Total
White9363277
Black or African American1315
American Indian or Alaska Native0011
Chinese0044
Japanese8131334
Korean2204
Not Reported09918
Other0112
More than One Race0011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Ravulizumab: Stage 1Ravulizumab: Stage 2Placebo: Stage 2Total
Not of Hispanic, Latino/a, or Spanish Origin15424097
Mexican, Mexican American, Chicano/a0011
Another Hispanic, Latino/a or Spanish Origin5111228
Not Reported010818
Unknown0112
08

Study locations

66 sites
  • Research Site
    Tampa, Florida 33612, United States
  • Research Site
    Grosse Pointe Farms, Michigan 48236, United States
  • Research Site
    Durham, North Carolina 27705, United States
  • Research Site
    Pittsburgh, Pennsylvania 15232, United States
  • Research Site
    Seattle, Washington 98109, United States
  • Research Site
    Parkville, 3050, Australia
  • Research Site
    Bruges, 8000, Belgium
  • Research Site
    Brussels, 1200, Belgium
  • Research Site
    Chênée, 4032, Belgium
  • Research Site
    Yvoir, 5530, Belgium
  • Research Site
    Cerqueira César, 05403-000, Brazil
  • Research Site
    Florianópolis, 88034-000, Brazil
  • Research Site
    Jaú, 17210-080, Brazil
  • Research Site
    Porto Alegre, 90035-903, Brazil
  • Research Site
    Porto Alegre, 90110-270, Brazil
  • Research Site
    Rio de Janeiro, 20230-130, Brazil
  • Research Site
    São José do Rio Preto, 15090-000, Brazil
  • Research Site
    São Paulo, 05.403-010, Brazil
  • Research Site
    Calgary, Alberta T2N 4N1, Canada
  • Research Site
    Suzhou, 215006, China
  • Research Site
    Tianjin, 300020, China
  • Research Site
    Angers, 49033, France
  • Research Site
    La Tronche, 38043, France
  • Research Site
    Nice, 06200, France
  • Research Site
    Hamburg, 20246, Germany
  • Research Site
    Ulm, 89081, Germany
  • Research Site
    Athens, 12462, Greece
  • Research Site
    Pátrai, 26504, Greece
  • Research Site
    Thessaloniki, 57010, Greece
  • Research Site
    Halfa, 31096, Israel
  • Research Site
    Ramat Gan, 52621, Israel
  • Research Site
    Roma, 00168, Italy
  • Research Site
    Udine, 33100, Italy
  • Research Site
    Akita, 010-8543, Japan
  • Research Site
    Anjo, 446-8602, Japan
  • Research Site
    Chiba, 260-8677, Japan
  • Research Site
    Fukushima, 960-1295, Japan
  • Research Site
    Isehara-shi, 259-1193, Japan
  • Research Site
    Kurashiki-shi, 710-8602, Japan
  • Research Site
    Minatoku, 105-8470, Japan
  • Research Site
    Okayama, 700-8558, Japan
  • Research Site
    Osaka, 545-8586, Japan
  • Research Site
    Osakasayama-shi, 589-8511, Japan
  • Research Site
    Sapporo, 060-8638, Japan
  • Research Site
    Suita-shi, 565-0871, Japan
  • Research Site
    Tsukuba, 305-8576, Japan
  • Research Site
    Wakayama, 641-8510, Japan
  • Research Site
    Groningen, 9713 GZ, Netherlands
  • Research Site
    Goyang-si, 10408, South Korea
  • Research Site
    Seoul, 03080, South Korea
  • Research Site
    Seoul, 03722, South Korea
  • Research Site
    Seoul, 06351, South Korea
  • Research Site
    Barcelona, 08036, Spain
  • Research Site
    Granada, 18014, Spain
  • Research Site
    L'Hospitalet de Llobregat, 08908, Spain
  • Research Site
    Madrid, 28007, Spain
  • Research Site
    Madrid, 28034, Spain
  • Research Site
    Madrid, 28040, Spain
  • Research Site
    Madrid, 28046, Spain
  • Research Site
    Málaga, 29010, Spain
  • Research Site
    Pamplona, 31008, Spain
  • Research Site
    Salamanca, 37007, Spain
  • Research Site
    Seville, 41013, Spain
  • Research Site
    Huddinge, 141 57, Sweden
  • Research Site
    London, W12 0HS, United Kingdom
  • Research Site
    Nottingham, NG5 1PB, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2020 to primary completion in Sep 2025, 57 months.

Results were first posted in Nov 2026, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2020
First posted
Sep 10, 2020
StartActual
Dec 10, 2020
Primary completionActual
Sep 19, 2025
CompletionActual
Mar 20, 2026
Results first posted
Nov 4, 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 4, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Event Free SurvivalNow Stage 2: Proportion of Participants With Event-free Survival During the 26-week Treatment PeriodTime frame: 26 weeks (treatment period) → Up to Week 26
Nov 4, 2026
Documents
Secondary outcomes
4 edited, 20 added, 6 removed, 6 more
What changed in the outcomes
  • EditedStage 2: Overall SurvivalTime frame: Day 100, 26 weeks (treatment period), and 52 weeks → Up to Day 100 (Treatment Period), Week 26 (Treatment Period), and Week 52 (Follow-up Period)
  • EditedStage 2: Non-relapse MortalityTime frame: Day 100, 26 weeks (treatment period), and 52 weeks → Baseline through Day 100 (Treatment Period), Week 26 (Treatment Period), and Week 52 (Follow-up Period)
  • EditedLossStage 2: Duration of TMA ResponseTime frame: 26 weeks (treatment period) → Baseline through Week 52
  • EditedStage 2: Change from baselineFrom Baseline in Number of Participants With TMA-associated organ dysfunctionOrgan Dysfunction in renal system, cardiovascular system, pulmonary system, CNS,the Renal System Through Week 26 and GI systemWeek 52Time frame: 26 weeks (treatment period) and 52 weeks → Baseline, Week 26 (Treatment Period), Week 52 (Follow-up Period)
  • AddedStage 2: Mean Number of Thrombotic Microangiopathy (TMA) Response Criteria Met During the 26-week Treatment PeriodTime frame: Baseline through Week 26
  • AddedStage 2: Percentage of Participants With Hematologic Response During the 26-week Treatment PeriodTime frame: Baseline through Week 26
  • AddedStage 2: Change From Baseline in the Estimated Glomerular Filtration Rate (eGFR) at Week 26 and Week 52Time frame: Baseline, Week 26 (Treatment Period), Week 52 (Follow-up Period)
  • AddedStage 2: Percentage of Participants With TMA Response During the 26-week Treatment PeriodTime frame: Baseline through Week 26
  • AddedStage 2: Cumulative Proportion of Participants Who Experienced a Complete TMA Response During the 26-week Treatment PeriodTime frame: Baseline through Week 26
  • AddedStage 2: Cumulative Proportion of Participants Experiencing Each Individual Component of TMA During the 26-week Treatment PeriodTime frame: Baseline through Week 26
  • AddedStage 2: Cumulative Proportion of Participants Experiencing a Hematologic Response During the 26-week Treatment PeriodTime frame: Baseline through Week 26
  • AddedStage 2: Percentage of Participants With Hemoglobin Response During the 26-week Treatment PeriodTime frame: Baseline through Week 26
  • AddedStage 2: Percentage of Participants With Platelet Response During the 26-week Treatment PeriodTime frame: Baseline through Week 26
  • AddedStage 2: Percentage of Participants With Partial Response During the 26-week Treatment PeriodTime frame: Baseline through Week 26
  • AddedStage 2: Percentage of Participants With Loss of TMA Response During the 26-week Treatment PeriodTime frame: Baseline through Week 26
  • AddedStage 2: Change From Baseline in Haptoglobin at Week 26 and Week 52Time frame: Baseline, Week 26 (Treatment Period), Week 52 (Follow-up Period)
  • AddedStage 2: Change From Baseline in Platelets at Week 26 and Week 52Time frame: Baseline, Week 26 (Treatment Period), Week 52 (Follow-up Period)
  • AddedStage 2: Change From Baseline in LDH at Week 26 and Week 52Time frame: Baseline, Week 26 (Treatment Period), Week 52 (Follow-up Period)
  • AddedStage 2: Change From Baseline in Hemoglobin at Week 26 and Week 52Time frame: Baseline, Week 26 (Treatment Period), Week 52 (Follow-up Period)
  • AddedStage 2: Percentage of Participants With Modified TMA Response During the 26-week Treatment PeriodTime frame: Baseline through Week 26
  • AddedStage 2: Change From Baseline in Number of Participants With TMA-associated Organ Dysfunction in the Cardiopulmonary System Through Week 26 and Week 52Time frame: Baseline, Week 26 (Treatment Period), Week 52 (Follow-up Period)
  • AddedStage 2: Change From Baseline in Number of Participants With TMA-associated Organ Dysfunction in the Central Nervous System Through Week 26 and Week 52Time frame: Baseline, Week 26 (Treatment Period), Week 52 (Follow-up Period)
  • AddedStage 2: Change From Baseline in Number of Participants With TMA-associated Organ Dysfunction in the Gastrointestinal System Through Week 26 and Week 52Time frame: Baseline, Week 26 (Treatment Period), Week 52 (Follow-up Period)
  • AddedStage 2: Percentage of Participants With TMA RelapseTime frame: Baseline through Week 52
  • RemovedTime To TMA ResponseTime frame: 26 weeks (treatment period)
  • RemovedChange from Baseline in eGFRTime frame: 26 weeks (treatment period) and 52 weeks
  • RemovedHematologic ResponseTime frame: 26 weeks (treatment period)
  • RemovedTMA response and time to response for each individual component of TMATime frame: 26 weeks (treatment period)
  • RemovedTime to Hematologic ResponseTime frame: 26 weeks (treatment period)
  • RemovedHemoglobin ResponseTime frame: 26 weeks (treatment period)
  • …and 6 more, on the record history on ClinicalTrials.gov ↗
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Event Free SurvivalNow Stage 2: Proportion of Participants With Event-free Survival During the 26-week Treatment PeriodTime frame: 26 weeks (treatment period) → Up to Week 26
    Secondary outcomes 4 edited, 20 added, 6 removed, 6 more
    What changed in the outcomes
    • EditedStage 2: Overall SurvivalTime frame: Day 100, 26 weeks (treatment period), and 52 weeks → Up to Day 100 (Treatment Period), Week 26 (Treatment Period), and Week 52 (Follow-up Period)
    • EditedStage 2: Non-relapse MortalityTime frame: Day 100, 26 weeks (treatment period), and 52 weeks → Baseline through Day 100 (Treatment Period), Week 26 (Treatment Period), and Week 52 (Follow-up Period)
    • EditedLossStage 2: Duration of TMA ResponseTime frame: 26 weeks (treatment period) → Baseline through Week 52
    • EditedStage 2: Change from baselineFrom Baseline in Number of Participants With TMA-associated organ dysfunctionOrgan Dysfunction in renal system, cardiovascular system, pulmonary system, CNS,the Renal System Through Week 26 and GI systemWeek 52Time frame: 26 weeks (treatment period) and 52 weeks → Baseline, Week 26 (Treatment Period), Week 52 (Follow-up Period)
    • AddedStage 2: Mean Number of Thrombotic Microangiopathy (TMA) Response Criteria Met During the 26-week Treatment PeriodTime frame: Baseline through Week 26
    • AddedStage 2: Percentage of Participants With Hematologic Response During the 26-week Treatment PeriodTime frame: Baseline through Week 26
    • AddedStage 2: Change From Baseline in the Estimated Glomerular Filtration Rate (eGFR) at Week 26 and Week 52Time frame: Baseline, Week 26 (Treatment Period), Week 52 (Follow-up Period)
    • AddedStage 2: Percentage of Participants With TMA Response During the 26-week Treatment PeriodTime frame: Baseline through Week 26
    • AddedStage 2: Cumulative Proportion of Participants Who Experienced a Complete TMA Response During the 26-week Treatment PeriodTime frame: Baseline through Week 26
    • AddedStage 2: Cumulative Proportion of Participants Experiencing Each Individual Component of TMA During the 26-week Treatment PeriodTime frame: Baseline through Week 26
    • AddedStage 2: Cumulative Proportion of Participants Experiencing a Hematologic Response During the 26-week Treatment PeriodTime frame: Baseline through Week 26
    • AddedStage 2: Percentage of Participants With Hemoglobin Response During the 26-week Treatment PeriodTime frame: Baseline through Week 26
    • AddedStage 2: Percentage of Participants With Platelet Response During the 26-week Treatment PeriodTime frame: Baseline through Week 26
    • AddedStage 2: Percentage of Participants With Partial Response During the 26-week Treatment PeriodTime frame: Baseline through Week 26
    • AddedStage 2: Percentage of Participants With Loss of TMA Response During the 26-week Treatment PeriodTime frame: Baseline through Week 26
    • AddedStage 2: Change From Baseline in Haptoglobin at Week 26 and Week 52Time frame: Baseline, Week 26 (Treatment Period), Week 52 (Follow-up Period)
    • AddedStage 2: Change From Baseline in Platelets at Week 26 and Week 52Time frame: Baseline, Week 26 (Treatment Period), Week 52 (Follow-up Period)
    • AddedStage 2: Change From Baseline in LDH at Week 26 and Week 52Time frame: Baseline, Week 26 (Treatment Period), Week 52 (Follow-up Period)
    • AddedStage 2: Change From Baseline in Hemoglobin at Week 26 and Week 52Time frame: Baseline, Week 26 (Treatment Period), Week 52 (Follow-up Period)
    • AddedStage 2: Percentage of Participants With Modified TMA Response During the 26-week Treatment PeriodTime frame: Baseline through Week 26
    • AddedStage 2: Change From Baseline in Number of Participants With TMA-associated Organ Dysfunction in the Cardiopulmonary System Through Week 26 and Week 52Time frame: Baseline, Week 26 (Treatment Period), Week 52 (Follow-up Period)
    • AddedStage 2: Change From Baseline in Number of Participants With TMA-associated Organ Dysfunction in the Central Nervous System Through Week 26 and Week 52Time frame: Baseline, Week 26 (Treatment Period), Week 52 (Follow-up Period)
    • AddedStage 2: Change From Baseline in Number of Participants With TMA-associated Organ Dysfunction in the Gastrointestinal System Through Week 26 and Week 52Time frame: Baseline, Week 26 (Treatment Period), Week 52 (Follow-up Period)
    • AddedStage 2: Percentage of Participants With TMA RelapseTime frame: Baseline through Week 52
    • RemovedTime To TMA ResponseTime frame: 26 weeks (treatment period)
    • RemovedChange from Baseline in eGFRTime frame: 26 weeks (treatment period) and 52 weeks
    • RemovedHematologic ResponseTime frame: 26 weeks (treatment period)
    • RemovedTMA response and time to response for each individual component of TMATime frame: 26 weeks (treatment period)
    • RemovedTime to Hematologic ResponseTime frame: 26 weeks (treatment period)
    • RemovedHemoglobin ResponseTime frame: 26 weeks (treatment period)
    • …and 6 more, on the record history on ClinicalTrials.gov ↗
    + 3 other changes: identifiers, verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04543591
Responsible party
Sponsor
First posted
Sep 10, 2020
Start date
Dec 10, 2020
Primary completion
Sep 19, 2025
Completion
Mar 20, 2026
Results posted
Nov 4, 2026
Last update
Nov 4, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ravulizumab

Start the discussion